JP Morgan: Reiterate "overweight" rating on COSCO Shipping Energy Transportation (01138), expected to benefit from the reopening of the Strait of Hormuz.
The bank believes that the recent weakness in oil tanker stocks reflects a decrease in market confidence in panic buying instead of a deterioration in the industry fundamentals.
JPMorgan Chase published a research report stating that the United States and Iran have reached a peace agreement, greatly increasing the possibility of the reopening of the Strait of Hormuz, which will bring a positive catalyst to oil tanker stocks. The reopening of the strait will increase the likelihood of normalizing crude oil purchase activities and inventory rebuilding, thereby driving oil tanker demand. The report reiterated a "buy" rating for COSCO Shipping Energy Transportation (01138) with a target price of 27 Hong Kong dollars.
The report points out that since the Middle East conflict, the market has lost approximately 1.3 billion barrels of oil supply, causing the market to switch to importing from countries with longer voyages such as the United States, West Africa, and Brazil, pushing Very Large Crude Carrier (VLCC) freight rates to above historical averages. The bank believes that the recent weakness in oil tanker stock prices reflects a weakening of market confidence in panic inventory building, rather than deterioration of industry fundamentals.
Related Articles

New Stocks Outlook | Ningbo Yunsheng: After the performance "squat jump", how should we view the growth potential?

New Stock News | Zhii Biotech filed an application to the Hong Kong Stock Exchange. Its core product SK08 and key product SK10 have achieved multiple research and development milestones.

New Stock News | Zhiyi Biotech Submits Listing Application to the Hong Kong Stock Exchange
New Stocks Outlook | Ningbo Yunsheng: After the performance "squat jump", how should we view the growth potential?

New Stock News | Zhii Biotech filed an application to the Hong Kong Stock Exchange. Its core product SK08 and key product SK10 have achieved multiple research and development milestones.

New Stock News | Zhiyi Biotech Submits Listing Application to the Hong Kong Stock Exchange

RECOMMEND





